Mitogenic effects of phosphatidylcholine nanoparticles on MCF-7 breast cancer cells.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE
    • Publication Information:
      Original Publication: New York, NY : Hindawi Pub. Co.
    • Subject Terms:
      Drug Delivery Systems* ; Mitogens*/chemistry ; Mitogens*/pharmacology ; Phosphatidylcholines*/chemistry ; Phosphatidylcholines*/pharmacology; Breast Neoplasms/*drug therapy ; Cell Proliferation/*drug effects ; MAP Kinase Signaling System/*drug effects ; Nanoparticles/*chemistry; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Cell Line, Tumor ; ErbB Receptors/metabolism ; Female ; Humans ; Neoplasm Proteins/metabolism
    • Abstract:
      Lecithins, mainly composed of the phospholipids phosphatidylcholines (PC), have many different uses in the pharmaceutical and clinical field. PC are involved in structural and biological functions as membrane trafficking processes and cellular signaling. Considering the increasing applications of lecithin-based nanosystems for the delivery of therapeutic agents, the aim of the present work was to determine the effects of phosphatidylcholine nanoparticles over breast cancer cellular proliferation and signaling. PC dispersions at 0.01 and 0.1% (w/v) prepared in buffer pH 7.0 and 5.0 were studied in the MCF-7 breast cancer cell line. Neutral 0.1% PC-derived nanoparticles induced the activation of the MEK-ERK1/2 pathway, increased cell viability and induced a 1.2 fold raise in proliferation. These biological effects correlated with the increase of epidermal growth factor receptor (EGFR) content and its altered cellular localization. Results suggest that nanoparticles derived from PC dispersion prepared in buffer pH 7.0 may induce physicochemical changes in the plasma membrane of cancer cells which may affect EGFR cellular localization and/or activity, increasing activation of the MEK-ERK1/2 pathway and inducing proliferation. Results from the present study suggest that possible biological effects of delivery systems based on lecithin nanoparticles should be taken into account in pharmaceutical formulation design.
    • References:
      Proc Natl Acad Sci U S A. 2011 May 31;108(22):9044-8. (PMID: 21571640)
      Pharmacol Ther. 2002 Apr-May;94(1-2):35-50. (PMID: 12191592)
      Prog Lipid Res. 2008 Sep;47(5):340-7. (PMID: 18424270)
      Nat Rev Mol Cell Biol. 2002 Dec;3(12):893-905. (PMID: 12461556)
      EMBO J. 1994 Apr 1;13(7):1610-9. (PMID: 8157000)
      Oncogene. 2010 Oct 28;29(43):5850-60. (PMID: 20676128)
      Int J Pharm. 2009 Sep 8;379(1):174-80. (PMID: 19524029)
      Int J Pharm. 2002 Oct 10;246(1-2):203-6. (PMID: 12270623)
      Trans Am Neurol Assoc. 1978;103:95-9. (PMID: 757093)
      Curr Opin Cell Biol. 2008 Aug;20(4):408-14. (PMID: 18502633)
      J Drug Deliv. 2012;2012:986265. (PMID: 22570790)
      Cell. 2012 Apr 13;149(2):274-93. (PMID: 22500797)
      ScientificWorldJournal. 2010 Jul 07;10:1356-69. (PMID: 20623096)
      Eur J Immunol. 2007 Oct;37(10):2912-22. (PMID: 17899539)
      Chem Pharm Bull (Tokyo). 2008 Jan;56(1):70-4. (PMID: 18175978)
      Pharmacogenomics. 2006 Oct;7(7):1109-23. (PMID: 17054420)
      Biochem J. 2000 Oct 15;351 Pt 2:459-67. (PMID: 11023832)
      Cell. 2006 Jun 16;125(6):1137-49. (PMID: 16777603)
      Diabet Med. 1992 May;9(4):335-40. (PMID: 1600703)
      J Biol Chem. 2000 Aug 4;275(31):23911-8. (PMID: 10801816)
      Biochim Biophys Acta. 1994 Apr 14;1212(1):26-42. (PMID: 8155724)
      Science. 2001 Nov 30;294(5548):1942-5. (PMID: 11729323)
      Int J Pharm. 2010 Jun 30;393(1-2):17-31. (PMID: 20417699)
      Mol Cancer Res. 2003 Sep;1(11):789-800. (PMID: 14517341)
      J Biol Chem. 1997 Apr 25;272(17):11011-6. (PMID: 9110992)
      Cell Signal. 2002 May;14(5):381-95. (PMID: 11882383)
      Biochim Biophys Acta. 2009 Sep;1791(9):845-9. (PMID: 19540357)
      Dev Cell. 2003 Oct;5(4):559-70. (PMID: 14536058)
      Cell. 2001 Oct 19;107(2):161-71. (PMID: 11672524)
      Future Oncol. 2009 Nov;5(9):1477-86. (PMID: 19903073)
      Breast Cancer Res. 2010;12(3):R27. (PMID: 20462431)
      Biochem Biophys Res Commun. 2002 Oct 4;297(4):1043-8. (PMID: 12359261)
      Nature. 2009 Mar 26;458(7237):445-52. (PMID: 19325624)
      J Endocrinol. 2010 Mar;204(3):299-309. (PMID: 20032199)
      Breast Cancer Res. 2011;13(6):224. (PMID: 22114931)
      Cell. 2002 Jan 25;108(2):261-9. (PMID: 11832215)
      Oncogene. 2011 Jul 28;30(30):3370-80. (PMID: 21423211)
      Anal Biochem. 1990 Mar;185(2):377-82. (PMID: 2339793)
      J Biol Chem. 1999 Jan 8;274(2):1131-9. (PMID: 9873061)
      J Pharm Pharmacol. 1994 Jan;46(1):78-9. (PMID: 8201532)
      Leukemia. 2004 Feb;18(2):189-218. (PMID: 14737178)
      Science. 1996 Dec 20;274(5295):2086-9. (PMID: 8953040)
      Oncogene. 1993 Nov;8(11):2959-68. (PMID: 8414498)
      Expert Opin Ther Targets. 2011 Jul;15(7):859-72. (PMID: 21476875)
      J Biol Chem. 2009 Aug 14;284(33):22322-22331. (PMID: 19525236)
    • Accession Number:
      0 (Mitogens)
      0 (Neoplasm Proteins)
      0 (Phosphatidylcholines)
      EC 2.7.10.1 (EGFR protein, human)
      EC 2.7.10.1 (ErbB Receptors)
    • Publication Date:
      Date Created: 20140429 Date Completed: 20141121 Latest Revision: 20211021
    • Publication Date:
      20221213
    • Accession Number:
      PMC3977480
    • Accession Number:
      10.1155/2014/687037
    • Accession Number:
      24772432